Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 201–300 of 1,000
Debbi, K., Grellier, N., Loganadane, G., Boukhobza, C., Mahé, M., Chérif, M., Rida, H., Gligorov, J., & Belkacémi, Y. (2023) · Cancers · doi:10.3390/cancers15082278 · Cited by 42
“Its combination with trastuzumab showed greater anti-tumor activity in vitro and in vivo, compared to each of the drugs used alone [48].”
BackgroundYang, Z., Meng, J., Mei, X., Mo, M., Xiao, Q., Han, X., Zhang, L., Shi, W., Chen, X., Ma, J., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5791 · Cited by 39
Koide, Y., Nagai, N., Adachi, S., Ito, M., Kawamura, M., Ito, M., Ito, F., Shindo, Y., Aoyama, T., Shimizu, H., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04681-8 · Cited by 39
“Among these advancements, particularly in HER2-positive breast cancer, the emergence of new systemic therapy management using the HER2CLIMB regimens or antibody–drug conjugates (ADCs), including trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), has shown promising results [4–13].”
InfluentialLeptomeningeal Metastases: New Opportunities in the Modern Era
Wilcox, J. A., Li, M., & Boire, A. A. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01261-4 · Cited by 40
“Tucatinib, a highly-selective third-generation HER2TKI, demonstrated compelling intracranial activity in the HER2CLIMB trial, which evaluated tucatinib or placebo in combination with trastuzumab and capecitabine in patients with previously-treated HER2+ breast cancer [108].”
BackgroundSystemic Therapy in Breast Cancer
Corti, C., Batra-Sharma, H., Kelsten, M. F., Shatsky, R. A., Garrido-Castro, A. C., & Gradishar, W. J. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432442 · Cited by 42
Thanopoulou, E., Khader, L., Caira, M., Wardley, A. M., Ettl, J., Miglietta, F., Neven, P., & Guarneri, V. (2020) · Cancers · doi:10.3390/cancers12113317 · Cited by 39
“In the recently reported HER2CLIMB trial, the addition of tucatinib to trastuzumab and capecitabine resulted in a clinically significant and meaningful improvement in PFS and OS compared with trastuzumab and capecitabine therapy (OS median 21.9 vs. 17.4 months; hazard ratio 0.66; 95% CI 0.50–0.88; p = 0.005) in patien…”
BackgroundInfluentialTargeting HER2 genomic alterations in non-small cell lung cancer
Zeng, J., Ma, W., Young, R. B., & Li, T. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.04.001 · Cited by 49
“In vitro tucatinib inhibits phosphorylation of HER2 and HER3, which results in blockade of downstream PI3K/AKT and Ras/MAPK signaling pathways, thus inhibiting cell growth 60 , 61 .”
BackgroundA small-molecule activator of the unfolded protein response eradicates human breast tumors in mice
Boudreau, M. W., Duraki, D., WANG, L. C. H., Mao, C., Kim, J. E., Henn, M. A., Tang, B., Fanning, S. W., Kiefer, J., Tarasow, T. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1383 · Cited by 40
Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer
Ring, A., Campo, D., Porras, T. B., Kaur, P., Forte, V. A., Tripathy, D., Lu, J. M., Kang, I. M., Press, M. F., Jeong, Y. J., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11135-2 · Cited by 47
“part due to the availability of targeted therapies.(4,5) Most patients with MBC unfortunately develop treatment resistance.”
BackgroundBreast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
Ivanova, M. D., Porta, F. M., Giugliano, F., Frascarelli, C., Sajjadi, E., Venetis, K., Cursano, G., Mazzarol, G., Guerini‐Rocco, E., Curigliano, G., et al. (2023) · Genes · doi:10.3390/genes14061160 · Cited by 44
“The randomized, double-blind, placebo-controlled HER2CLIMB clinical trial (NCT02614794) compared a small-molecule highly selective for HER2 oral tyrosine kinase inhibitor (TKI), tucatinib, versus placebo in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic BC previously treated wi…”
BackgroundSelf-citationSchlam, I. M., Church, S., HETHER, T. D., Chaldekas, K. M., Hudson, B. M., White, A. M., Maisonet, E., Harris, B. T., & Swain, S. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03113-9 · Cited by 40
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
Noblejas‐López, M. D. M., Gandullo‐Sánchez, L., Galán‐Moya, E. M., López‐Rosa, R., Tébar-García, D., Nieto‐Jiménez, C., Sango, M. G., Burgos, M., Pandiella, A., & Ocaña, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105476 · Cited by 36
Olson, D. J., Taylor, J., Willis, K., Hensley, K. M., Allred, S., Zaval, M. C., Farr, L., Thurman, R., Jain, N., Hein, R. F. C., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0302 · Cited by 35
“In translation to clinical practice, the combination of tuca-tinib, trastuzumab, and capecitabine has been shown to significantly improve outcomes over trastuzumab and capecitabine in patients with metastatic breast cancer, including those with active brain metastases (17, 19–21).”
BackgroundM2 macrophages promote PD-L1 expression in triple-negative breast cancer via secreting CXCL1
Zhang, L., Gu, S., Wang, L., Zhao, L., Li, T., Zhao, X., & Zhang, L. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155458 · Cited by 40
Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier
Omidi, Y., Kianinejad, N., Kwon, Y. M., & Omidian, H. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1887729 · Cited by 36
“Tukusa® (tukatynib) Brain metastasis of HER2+ breast cancer 04/2020 Tyrosine-kinase inhibitor of HER2 Seattle Genetics [92]”
BackgroundRecent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
Kahraman, S., & Yalçın, Ş. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s315252 · Cited by 40
“atinib, was approved by the Food and Drug Administration (FDA) based on data from the pivotal HER2CLIMB trial for the treatment of patients with advanced HER2-positive breast cancer, including those with brain metastases, in combination with trastuzumab and capecitabine after at least one round of anti-HER2 treatment.…”
MethodGarber, H. R., Raghavendra, A. S., Lehner, M., Qiao, W., Gutierrez‐Barrera, A. M., Tripathy, D., Arun, B., & Ibrahim, N. K. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00407-z · Cited by 38
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Koirala, N., Dey, N., Aske, J. C., & De, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126547 · Cited by 36
“Tucatinib HER2 HER2CLIMB (NCT02614794) [35] 3rd line: Metastatic HER2-positive BC, including patients with brain metastases, with one or more prior anti-HER2 regimens in the metastatic setting (2020).”
BackgroundThill, M., Kolberg‐Liedtke, C., Albert, U., Banys-Paluchowski, M. J., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Ditsch, N., Fallenberg, E. M., et al. (2023) · Breast Care · doi:10.1159/000531579 · Cited by 35
Self-citationLatham, B. D., Geffert, R. M., & Jackson, K. D. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001430 · Cited by 36
Li, J., Wang, Z. H., Chen, L., Zhang, W. J., Ma, L., Wu, J., Liu, G. Y., Hou, Y. F., Yu, K., Di, G., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.011 · Cited by 34
Genetics and Genomics of Breast Cancer: update and translational perspectives
Biancolella, M., Testa, B., Salehi, L. B., D’Apice, M. R., & Novelli, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.013 · Cited by 35
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
Bartsch, R. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1792443 · Cited by 35
Suwanvecho, S., Suwanrusme, H., Jirakulaporn, T., Issarachai, S. S., Taechakraichana, N., Lungchukiet, P., Decha, W., Boonpakdee, W., Thanakarn, N., Wongrattananon, P., et al. (2021) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa334 · Cited by 34
Spring, L. M., Clark, S. L., Li, T., Goel, S., Tayob, N., Viscosi, E., Abraham, E., Juric, D., Isakoff, S. J., Mayer, E. L., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00311-y · Cited by 36
O'Sullivan, C. C., Ballman, K. V., McCall, L. M., Kommalapati, A., Zemla, T., Weiss, A. C., Mitchell, M. P., Blinder, V. S., Tung, N., Irvin, W. J., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0753 · Cited by 37
Self-citationThill, M., Friedrich, M., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2021) · Breast Care · doi:10.1159/000516420 · Cited by 34
Self-citationO'Brien, N. A., Huang, H., McDermott, M. S. J., Madrid, A. M., Luo, T., Ayala, R., Issakhanian, S., Gong, K. W., Lu, M., Zhang, J., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0847 · Cited by 39
Self-citationMasri, J. E., & Phadke, S. D. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000721 · Cited by 45
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan, M., Wang, X., Ascha, M. S., Miksad, R. A., Showalter, T. N., Calip, G. S., Gross, C. P., & Adelson, K. B. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1129 · Cited by 35
Pharmacotherapy for leptomeningeal disease in breast cancer
Bartsch, R., Jerzak, K. J., Larrouquère, L., Müller, V., & Rhun, É. L. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102653 · Cited by 35
Self-citationTemozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Zimmer, A. S., Steinberg, S. M., Smart, D. D., Gilbert, M. R., Armstrong, T. S., Burton, E., Houston, N. D., Biassou, N. M., Gril, B., Brastianos, P. K., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0094 · Cited by 37
“Based on that, the HER2CLIMB Phase III trial was developed, with results recently reported [45].”
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications
Jin, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072255 · Cited by 35
Khan, M. B., Zhao, Z., Arooj, S., Zheng, T., & Liao, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576926 · Cited by 33
Bergen, E. S., Binter, A., Starzer, A. M., Heller, G., Kiesel, B., Tendl-Schulz, K., Bagó-Horváth, Z., Furtner, J., Leitner, J., Exner, R., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211009002 · Cited by 33
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 37
Page, D. B., Beal, K. P., Linch, S. N., Spinelli, K. J., Rodine, M., Halpenny, D. F., Modi, S., Patil, S. N., Young, R. J., Kaley, T. J., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00404-2 · Cited by 34
Epaillard, N., Bassil, J., & Pistilli, B. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102597 · Cited by 34
ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Tew, B. Y., Kalfa, A. J., Yang, Z., Hurth, K. M., Simon, T., Abnoosian, E., Durant, S. T., Hamerlik, P., & Salhia, B. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0290 · Cited by 35
“This includes ALK inhibitors for non – small cell lung cancer (9), HER2 inhibitors for HER2 þ breast cancer (10), and checkpoint inhibitors for melanoma (11).”
The History and Development of HER2 Inhibitors
Xia, X., Chen, G., Zhang, Y., & Xiong, H. (2023) · Pharmaceuticals · doi:10.3390/ph16101450 · Cited by 35
Topletz‐Erickson, A. R., Lee, A. J., Mayor, J. G., Rustia, E. L., Abdulrasool, L. I., Wise, A. L., Dailey, B., DeChenne, S., Walker, L. N., Alley, S. C., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1750 · Cited by 32
Self-citationClinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
Huang, R. S. P., Haberberger, J., McGregor, K., Mata, D. A., Decker, B. J., Hiemenz, M., Lechpammer, M., Danziger, N. A., Schiavone, K., Creeden, J., et al. (2021) · The Oncologist · doi:10.1002/onco.13855 · Cited by 35
“In contrast to these advances for the control of extracranial disease, only tucatinib has been specifically licensed for the treatment of BCBM and only in the context of HER2-positive disease, as patients with active BCBM have been excluded from the vast majority of registration trials in breast cancer [16].”
BackgroundSelf-citationAlvarez-Breckenridge, C. A., Remón, J., Piña, Y., Nieblas‐Bedolla, E., Forsyth, P. A., Hendriks, L. E. L., & Brastianos, P. K. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_352320 · Cited by 38
Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma
Augustin, J., Soussan, P., & Bass, A. J. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.001 · Cited by 37
Ma, H., Liu, Y., Miao, Z., Cheng, S., Zhu, Y., Wu, Y., Fan, X., Yang, J., Li, X., & Guo, L. (2022) · Drug Development Research · doi:10.1002/ddr.21983 · Cited by 32
“TheTKIs, including lapatinib, Neratinib and tucatinib, are officially approved by the FDA for the treatment of human epidermal growth factor‐2‐positive breast cancer (Murthy et al., 2020; Ryan et al., 2008; Singh et al., 2018).”
BackgroundChung, W., Huang, W.-L., Lee, C., Hsu, H., Huang, W., Liu, Y., & Su, W. (2022) · PubMed · Cited by 32
An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs
Gandullo‐Sánchez, L., & Pandiella, A. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216024 · Cited by 32
Molecular aspects of brain metastases in breast cancer
Tomasik, B., Bieńkowski, M., Górska, Z., Gutowska, K., Kumięga, P., Jassem, J., & Duchnowska, R. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102521 · Cited by 33
Signaling pathway dysregulation in breast cancer
Ryspayeva, D., Seyhan, A. A., MacDonald, W., Purcell, C., Roady, T. J., Ghandali, M., Verovkina, N., El‐Deiry, W. S., Taylor, M. S., & Graff, S. L. (2025) · Oncotarget · doi:10.18632/oncotarget.28701 · Cited by 33
Li, C., Bian, X., Liu, Z., Wang, X., Song, X., Zhao, W., Liu, Y., & Yu, Z. (2021) · Cancer Medicine · doi:10.1002/cam4.4335 · Cited by 31
The role of cGAS-STING signaling in ischemic stroke: From immune response to therapeutic targeting
Chauhan, C., & Kaundal, R. K. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103792 · Cited by 33
Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis
Routman, D. M., Chera, B. S., & Gupta, G. P. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000437 · Cited by 31
Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis
Blanco, M. N. F., Garcia, H. D., Legeai‐Mallet, L., & van Osch, G. J. V. M. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.07.003 · Cited by 34
Angeli, E., & Bousquet, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091446 · Cited by 32
Bedard, P. L., Li, S., Wisinski, K. B., Yang, E. S.-H., Limaye, S. A., Mitchell, E. P., Zwiebel, J. A., Moscow, J. A., Gray, R. J., Wang, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00165 · Cited by 30
Self-citationCancer Pain and Opioid Use Disorder
Ganguly, A. (2022) · ONCOLOGY · doi:10.46883/2022.25920973 · Cited by 30
Dong, Z., Huang, Z., Li, S., Wang, Y., Yao, Y., Yang, X., & Xu, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.021 · Cited by 32
Lazaratos, A.-M., Maritan, S. M., Quaiattini, A., Darlix, A., Ratoša, I., Ferraro, E., Griguolo, G., Guarneri, V., Pellerino, A., Höfer, S., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.04.008 · Cited by 30
“…Brufsky, A. and Pohlmann, P. R. and Park, D. M. and Park, B. H. and Krop, I. and Lin, N. U. and Wolff, A. and Forerro-Torres, A. and StringerReasor, E. Murthy 2020 Prospective trial Trial ongoing: currently 15 patients, accrual of 30 patients Determinants of prolonged survival for breast cancer…”
BackgroundHER2+ advanced gastric cancer: Current state and opportunities (Review)
Hu, H.-H., Wang, S., Zhao, H., Chen, Z., Shi, X., & Chen, X. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5624 · Cited by 32
“Tucatinib, a highly selective small molecule HER2‑targeted TKI, has been shown to markedly improve the oS of patients with breast cancer (132).”
BackgroundSalting the Soil: Targeting the Microenvironment of Brain Metastases
Srinivasan, E. S., Tan, A. C., Anders, C. K., Pendergast, A. M., Sipkins, D. A., Ashley, D. M., Fecci, P. E., & Khasraw, M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0579 · Cited by 30
Self-citationWong, C. W., Yost, S. E., Lee, J. S., Gillece, J. D., Folkerts, M., Reining, L., Highlander, S. K., Eftekhari, Z., Mortimer, J. E., & Yuan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.604584 · Cited by 33
Simmons, C. E., Rayson, D., Joy, A. A., Henning, J., Lemieux, J., McArthur, H. L., Card, P. B., Dent, R. A., & Brezden‐Masley, C. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211066677 · Cited by 29
Li, J., Jiang, J., Bao, X., Kumar, V., Alley, S. C., Peterson, S., & Lee, A. J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0405 · Cited by 29
“…placebo-controlled trial (HER2CLIMB) has provided strong evidence for the intracranial ef fi cacy and overall survival bene fi t of tucatinib in combination with trastuzumab and capecitabine among heavily pretreated HER2-positive breast cancer patients with active or stable brain metastases (11, 12).”
Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada
Wang, X. Y., Rosen, M. N., Chehade, R., Sahgal, A., Das, S., Warner, E., Saskin, R., Zhang, B., Soliman, H., Chan, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.25424 · Cited by 30
Therapeutic landscape of advanced HER2-positive breast cancer in 2022
Gupta, R., Gupta, S., Antonios, B., Ghimire, B., Jindal, V., Deol, J., Gaikazian, S., Huben, M. T., Anderson, J., Stender, M., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01849-y · Cited by 35
“Lin et al. conducted a separate analysis of patients in HER2CLIMB trial, focusing exclusively on CNS outcomes [55].”
BackgroundInfluentialXu, B., Li, W., Zhang, Q., Li, Q., Wang, X., Li, H., Sun, T., Yin, Y., Zheng, H. Y., Feng, J., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06775-1 · Cited by 30
Alrhmoun, S., & Sennikov, S. V. (2022) · Cancers · doi:10.3390/cancers14246173 · Cited by 29
“The benefits of TKIs also include oral administration and reduced cardiac toxicity, which means that patients who have developed congestive heart failure as a result of trastuzumab can be safely treated with TKIs [5,88].”
BackgroundInfluentialTargeted Therapies and Developing Precision Medicine in Gastric Cancer
Pihlak, R., Fong, C., & Starling, N. (2023) · Cancers · doi:10.3390/cancers15123248 · Cited by 30
“Tucatinib has been shown to be efficacious in HER2-positive breast and colorectal cancers [65,66], and the phase II/III MONTAINEER-02 trial will assess tucatinib, trastuzumab, ramucirumab and paclitaxel as second-line treatment in HER2-positive gastric cancers (NCT0449924) [67].”
BackgroundTyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
Yang, X. L., Wu, D., & Yuan, S. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962140 · Cited by 30
“Tucatinib is highly selective for HER2, has no effect on EGFR, and has less off-target effects like rashes and diarrhea.(26,28) It potently inhibits HER2 and HER3 through the MAPK and PI3K/AKT pathways.”
BackgroundTolaney, S. M., Goel, S., Nadal, J. C., Denys, H. G., Borrego, M. R., Litchfield, L. M., Liu, J., Appiah, A. K., Chen, Y., & André, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1209 · Cited by 33
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Okines, A. F. C., Curigliano, G., Mizuno, N., Oh, D., Rorive, A., Soliman, H. H., Takahashi, S., Bekaii‐Saab, T., Burkard, M. E., Chung, K. Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03462-0 · Cited by 30
“28) and approved in multiple geographic regions for treatment of previously treated HER2 + MBC (combined with trastuzumab and capecitabine) 11,29–31 and previously treated HER2 + metastatic colorectal cancer (combined with trastuzumab) 12 .”
Self-citationXie, Y., Xie, J., Huang, G., Zhang, J., Song, C., Luo, Y., Tang, H., Tang, Y., Xiao, X., Zhang, C., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217734 · Cited by 36
Breast Cancer: Molecular Pathogenesis and Targeted Therapy
Samad, M. A., Ahmad, I., Khan, M. R., Suhail, M., Zughaibi, T. A., Al-Abbasi, F. A., Alhosaini, K. A., Khan, M. S., Kumer, A., & Tabrez, S. S. M. (2025) · MedComm · doi:10.1002/mco2.70404 · Cited by 34
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Siegel, F., Siegel, S., Kotýnková, K., Uzunbas, G. K., Korr, D., Tomono, H., Andersen, S., Denney, D. R., Berger, M., Schulze, V., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0605 · Cited by 37
The Evolving Landscape of HER2-Directed Breast Cancer Therapy
Marti, J. L. G., Hyder, T., Nasrazadani, A., & Brufsky, A. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00780-6 · Cited by 29
Management of Brain and Leptomeningeal Metastases from Breast Cancer
Pellerino, A., Internò, V., Mo, F., Franchino, F., Soffietti, R., & Rudà, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228534 · Cited by 31
Clinical trial data and emerging strategies: HER2-positive breast cancer
Pernas, S., & Tolaney, S. M. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06575-7 · Cited by 29
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
Schlam, I. M., & Gatti-Mays, M. E. (2022) · The Oncologist · doi:10.1093/oncolo/oyac064 · Cited by 38
Müller, V., Bartsch, R., Lin, N., Montemurro, F., Pegram, M. D., & Tolaney, S. M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102527 · Cited by 30
Self-citationPyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
Qi, X., Shi, Q., Xuhong, J., Zhang, Y., & Jiang, J. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01694-5 · Cited by 28
“Clinical evidence has demonstrated the significant efficacy of TKIs such as lapatinib, neratinib, and tucatinib in patients with HER2-positive BC [31–34].”
BackgroundBrain metastasis in de novo breast cancer: An updated population-level study from SEER database
Sun, M.-S., Yun, Y.-Y., Liu, H., Yu, Z.-H., Yang, F., & Xu, L. (2022) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2021.12.037 · Cited by 32
Dieras, V. C., Curigliano, G., Martín, M., Lerebours, F., Tsurutani, J., Savard, M.-F., Jerzak, K. J., Hu, X., Pimentel, L. C. M. D. A., O'Sullivan, C. C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-02600 · Cited by 29
“9 In addition to the promising fi ndings of this primary analysis of HER2CLIMB-05, other recent advances are expanding the treatment options for HER2 1 MBC. 20,21 4/6 inhibitor, palbociclib, versus placebo to trastuzumab and pertuzumab with ET in patients with HER2 1 /hormone receptor – positive advanced/MBC who had co…”
InfluentialSelf-citationThird-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
Tarantino, P., Prat, A., Cortés, J., Cardoso, F., & Curigliano, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188487 · Cited by 27
Self-citationTargeting HER2 in breast cancer: new drugs and paradigms on the horizon
Tarantino, P., Morganti, S., & Curigliano, G. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00037 · Cited by 34
“I 13 46% NA NCT02892123 PRS-343 [55] Pieris Pharma, Inc.”
BackgroundInfluentialSelf-citationJackisch, C., Cortazar, P., Geyer, C. E., Gianni, L., Gligorov, J., Machackova, Z., Perez, E. A., Schneeweiß, A., Tolaney, S. M., Untch, M., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102229 · Cited by 29
Kearney, M., Franks, L. E., Lee, S. Y., Tiersten, A., Makower, D., Cigler, T., Mundi, P. S., Chi, D.-C., Goel, A., Klein, P., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06306-4 · Cited by 28
Chandra, S., Tan, E. Y., Empeslidis, T., & Sivaprasad, S. (2023) · Eye · doi:10.1038/s41433-023-02610-z · Cited by 28
“The HER-2-speci fi c TKI tucatinib is a drug approved for treating HER-2-positive metastatic breast cancer [19].”
BackgroundZou, H., Luo, J., Guo, Y., Deng, L., Zeng, L., Pan, Y., & Li, P. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101051 · Cited by 30
Hong, R., Xia, W., Wang, L., Lee, K., Lu, Q., Jiang, K., Li, S., Yu, J., Wei, J., Tang, W., et al. (2021) · 癌症:英文版 · doi:10.1002/cac2.12135 · Cited by 27
“lapatinib [7], neratinib [8], tucatinib [9], pertuzumab [4], ado-trastuzumab emtansine [T-DM1] [10], and trastuzumab deruxtecan [11]) have significantly improved the treatment outcomes of patients with HER2-positive breast cancer.”
BackgroundLi, W., Li, S., Chen, I. X., Liu, Y., Ramjiawan, R. R., Leung, S. C. H., Gerweck, L. E., Fukumura, D., Loeffler, J. S., Jain, R. K., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01775-9 · Cited by 32
Khatri, V. M., Mestres-Villanueva, M. A., Yarlagadda, S., Doniparthi, A., Smith, D. B., Nakashima, J. Y., Bryant, J. M., Zhao, D., Upadhyay, R., Mills, M. N., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00711-w · Cited by 29
The Role of Stereotactic Biopsy in Brain Metastases
Yu, K. K. H., Patel, A., & Moss, N. S. (2020) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2020.06.002 · Cited by 26
Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy
Jiang, M., Li, W., Zhu, C., Li, X., Zhang, J., Luo, Z., Qin, B., Du, Y., Luo, L., & You, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.031 · Cited by 26
Zhang, Y., Liu, Y., Xie, S., Xu, X., & Xu, R.-A. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2022.2048862 · Cited by 26
“Otherwise, the patient might suffer from some severe side effects (such as diarrhoea, palmar-plantar erythrodysesthesia syndrome and nausea) caused by increased tucatinib plasma levels (Murthy et al. 2020).”
BackgroundDevelopments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
Lebert, J. M., & Lilly, E. J. (2022) · Current Oncology · doi:10.3390/curroncol29040208 · Cited by 29
“These survival benefits were also accompanied by longer preservation of quality of life [11].”
BackgroundInfluentialSystemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era
Gión, M., Trapani, D., Cortés, A., Valenza, C., Lin, N., Cortés, J., & Curigliano, G. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351222 · Cited by 30
Self-citationSystemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
Cano, K. S. V., Castañeda, D. H. M., Escrivá-de-Romaní, S., & Saura, C. (2022) · Cancers · doi:10.3390/cancers15010051 · Cited by 30
“Previously treated brain metastases could be either stable since treatment or to have progressed since prior local CNS therapy, provided there was no clinical indication for immediate re-treatment with local therapy [51].”
BackgroundSEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
García-Sáenz, J. Á., Blancas, I., Echavarría, I., Hinojo, C., Vila, M. M., Moreno, F., Pernas, S., y Cajal, T. R., Ribelles, N., & Bellet, M. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03203-8 · Cited by 27
“(median of four prior lines of therapy, but no prior T-Dxd), PFS and OS rates were superior in patients receiving tucatinib–capecitabine–trastuzumab compared to those receiving capecitabine–trastuzumab only [44].”
BackgroundNewly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer
Graff, S. L., Yan, F., & Abdou, Y. G. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.05.003 · Cited by 27
Zheng, Y., Cao, W., Shao, X., Shi, Y., Cai, L., Chen, W., Liu, J., Shen, P., Chen, Y., Wang, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44140-y · Cited by 30
“The treatment paradigm for HER2-positive MBC is continually evolving, with new developments such as antibody-drug conjugates (ADCs) like trastuzumab deruxtecan 9,10 and TKIs including tucatinib 11,12 .”
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.